LTZ Therapeutics Raises $38M for Immunotherapy Pipeline
REDWOOD CITY, California, United States and SHENZHEN, China – May 6, 2026 LTZ Therapeutics has announced the successful completion...
Bispecific Antibody
Advertisement
Partner Therapeutics Gains FDA Priority Voucher for BIZENGRI®
LEXINGTON, Massachusetts, United States – May 6, 2026 Partner Therapeutics has announced that the U.S. Food and Drug Administration...
UCB to Acquire Candid Therapeutics in $2.2B Immunology Deal
SAN DIEGO, CALIFORNIA, May 03, 2026 UCB has announced a definitive agreement to acquire Candid Therapeutics in a transaction...
Kodiak KSI-101 Shows Strong MESI Clinical Trial Results
Palo Alto, California, United States | May 1, 2026 Kodiak Sciences Inc. has announced new clinical and pipeline advancements...
Pfizer ELREXFIO Phase 3 Trial Improves Survival Outcomes
New York, United States | April 29, 2026 Pfizer Inc. has reported positive Phase 3 clinical trial results for...
Advertisements
Bambusa Therapeutics Completes BBT001 Trial Enrollment
BOSTON, MASSACHUSETTS, April 30, 2026 Bambusa Therapeutics has announced the successful completion of patient enrollment in its Phase 1b/2a...
Novo Nordisk Reports Strong Phase 3 Results for Denecimig in Hemophilia A
PLAINSBORO, N.J. & BAGSVAERD, Denmark, April 29, 2026 Novo Nordisk has announced that its investigational therapy denecimig (Mim8) significantly...
Compass Therapeutics Nears Key Data for Tovecimig in BTC
Boston, Massachusetts | April 24, 2026 Compass Therapeutics has announced it will present topline secondary endpoint data from its...
Phanes Therapeutics Shows Progress in PDAC with Spevatamig
San Diego, California, USA – April 22, 2026 In a significant development in oncology drug innovation, Phanes Therapeutics has...
Akeso Cadonilimab Combo Shows Strong Survival in Pancreatic Cancer
Hong Kong, April 20, 2026 In a significant breakthrough in oncology immunotherapy, Akeso, Inc. has announced promising Phase II...
Advertisement
